Alluvi, previously BI 4744, presents a promising development in weight management therapy. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling efficacy in clinical trials, arguably exceeding https://alluvi-research.co.uk/product/alluvi-retatrutide-40mg-rd-only/